Articles

Sep 23, 2026

Semaglutide's appetite effect might start in the brain, not the gut

Semaglutide's receptor biology is well mapped, but whether its appetite effect runs through the vagus nerve or the brain directly is still disputed.

Sep 20, 2026

Tesamorelin peptide: FDA-approved for one job, marketed for many

Tesamorelin is FDA-approved for one narrow use in HIV-related fat gain. Here is what the human trials show, and where off-label marketing outruns the evidence.

Sep 19, 2026

Semax side effects: the trials never tested for them

Semax's stroke trials report mild effects, but none were designed to catch them. Here is what the human and animal data can and cannot show.

Sep 17, 2026

Does compounded semaglutide work? Only if the vial matches the trial.

Compounded semaglutide is the same peptide the STEP trials tested, but salt-form substitutes and dosing errors mean results do not automatically transfer.

Sep 16, 2026

Thymosin Alpha 1: The Sepsis Trial Nobody Selling It Mentions

Thymosin alpha 1 has randomized trial data in sepsis and hepatitis, not the immune optimization use it is marketed for. What the trials tested.

Sep 15, 2026

Selank has real anxiety trials. Most peptides don't.

Selank has small human trials behind it for anxiety, unlike most peptides sold online. What the studies measured, what they didn't, and what dosing they used.

Sep 14, 2026

Sermorelin Peptide Has Three Small Human Trials Behind It

Sermorelin peptide has real human trial data, but it's thin: small, short studies in older adults. Here's what they show and what they don't.

Sep 13, 2026

Hexarelin before and after: a growth hormone curve measured in hours

Hexarelin's best-documented effect is a growth hormone curve lasting about four hours, not a multi-week transformation, the human trials show.

Sep 12, 2026

Peptide calculator math is easy. Trusting the dose isn't.

A peptide calculator converts vial size and water volume into a dose. It cannot tell you whether that dose has ever been tested in a human trial.

Sep 10, 2026

Delta sleep inducing peptide: the human trials are thin and old

DSIP promised delta wave sleep in 1977. The human trials behind it are small, decades old and inconsistent about what it does.

Sep 8, 2026

CJC-1295's whole case rests on one 2006 dosing trial

CJC-1295's growth hormone effects rest on a single human dosing trial. Here is what it found, what it did not test, and what remains unproven.

Sep 7, 2026

GHK-Cu topical use has two human trials. Here's what they found.

GHK-Cu topical peptide has two human trials behind its anti-aging claims. Here's what they measured, what they found, and what remains unproven.

Sep 6, 2026

Ipamorelin's only human efficacy trial missed its endpoint

Ipamorelin raises growth hormone in small trials, but its one randomized efficacy trial did not beat placebo. Dosing, safety and what the data shows.

Sep 5, 2026

PT-141 benefits come down to one trial-tested effect

PT-141 (bremelanotide) benefits, per its two phase 3 trials: what changed for premenopausal women with low desire, and what the evidence does not establish.

Sep 4, 2026

Peptides to lose weight: which ones the trials back

Semaglutide and tirzepatide have randomized trial evidence for weight loss. Most other peptides sold for fat loss do not. Here is what separates them.

Sep 3, 2026

Selank's only randomized trial compared it to a drug, not a placebo

Selank's anxiolytic reputation rests on one small active-comparator trial from a single Russian lab. Here is what it showed, what it could not show, and what remains unproven.

Sep 2, 2026

Selank's side effects are barely documented in humans

Selank's safety record rests on one small Russian trial and animal studies. Here is what has been tested, what hasn't, and what stays unknown.

Sep 1, 2026

Is Ozempic a peptide? Yes, and one edit explains why it lasts a week

Semaglutide, the drug in Ozempic, is a 31-amino-acid peptide built from human GLP-1. Here is what the modification does and what the trials show.

Aug 31, 2026

KLOW peptide dosage: what the label numbers rest on

KLOW blends GHK-Cu, KPV, BPC-157 and TB-500. No trial has tested that combination. Here is what dosing data exists for each peptide alone.

Aug 29, 2026

GHK-Cu Peptide Side Effects: Topical Is Studied, Injections Aren't

GHK-Cu's human trial data covers topical cosmetic use, not injections. Here is what the published safety evidence covers and where it stops.

Aug 28, 2026

Copper peptide serum's real bottleneck is getting through your skin

Copper peptide serum claims lean on cell and animal data. Here is what the two human trials found and what limits skin penetration.

Aug 27, 2026

What a peptide reconstitution calculator cannot check for you

How peptide reconstitution calculators work, why unit and vial errors matter more than the arithmetic, and how to get an accurate dose.

Aug 26, 2026

Semax benefits are real in stroke trials, thin everywhere else

Semax's benefit claims rest on a small, Russian-concentrated body of trials in stroke and cognition. Here is what they found and what remains unproven.

Aug 25, 2026

Semax dosage: is there one standard protocol?

Semax has no standardized or FDA-approved dose. Here is what doses published trials used, and what remains unverified in humans.

Aug 24, 2026

5-Amino-1MQ works in mice. No study has tried it in people.

5-Amino-1MQ blocks NNMT and cuts fat mass in mice, with no published human trial. Here is what the evidence shows and what remains unproven.

Aug 23, 2026

Melanotan II before and after photos never show the one real risk

Melanotan II before and after photos are everywhere online. Here is what the human pilot trials and case reports establish, and what they do not.

Aug 21, 2026

Copper peptide before and after: the trial nobody can name

Most copper peptide before and after claims trace to review articles by the compound's own discoverer, not independent controlled trials.

Aug 20, 2026

How to read a peptide certificate of analysis, line by line

What each line on a peptide COA means, which numbers are load-bearing, and the difference between HPLC purity and how much peptide is in the vial.

Aug 20, 2026

How long bacteriostatic water lasts, and what the date measures

Bacteriostatic water carries a 28 day in-use convention. What that number is based on, where it came from, and why the peptide inside it has a different clock.

Aug 20, 2026

How to store peptides: temperatures, timelines and what ruins them

Lyophilised peptides go in the freezer, reconstituted vials go in the fridge and never the freezer. The temperatures, the timelines and the reasons behind each.

Aug 20, 2026

How to reconstitute peptides: the chemistry that decides the result

Reconstituting peptides is a stability problem, not a mixing problem. What the formulation literature says about diluent, technique, storage and shelf life.

Aug 20, 2026

Where to buy PT-141: the pharmacy route beats the vial online

Where to buy PT-141 safely: how FDA-approved Vyleesi differs from unregulated research-chemical vendors, and what the trial evidence supports.

Aug 20, 2026

Semax vs Selank: two Russian peptides, one shared evidence problem

Semax is an ACTH fragment analogue, Selank a tuftsin analogue. Both have registered Russian clinical use and almost nothing in the Western trial literature.

Aug 20, 2026

Ipamorelin vs sermorelin: one has human trials, the other has a paper

Both raise growth hormone through different receptors. Sermorelin went through human trials and clinical use. Ipamorelin's evidence stops at its founding paper.

Aug 20, 2026

Semaglutide vs tirzepatide vs retatrutide: what the trials measured

One, two and three receptors. The head-to-head trial data on weight reduction, the adverse event profiles, and what separates a finished drug from a phase 2 result.

Aug 20, 2026

The GLOW Protocol: Three Peptides, No Combined Evidence

The GLOW stack combines GHK-Cu, BPC-157 and TB-500. We checked the literature: not one study has tested the three together in people.

Aug 20, 2026

CJC-1295 and ipamorelin: real pharmacology, missing outcomes

The CJC-1295 and ipamorelin stack has genuine human pharmacology behind it. What is missing is any trial measuring what people take it for.

Aug 20, 2026

The Wolverine stack is two peptides doing the same job

The Wolverine stack pairs BPC-157 with TB-500. Both act on the same repair steps in the same rodent models, which makes the pairing redundant, not synergistic.

Aug 20, 2026

KLOW peptide protocol: four peptides, four separate literatures

KLOW adds KPV to the GLOW stack. We checked each component: the KPV work is mouse gut inflammation, and nothing tests the four together.

Aug 19, 2026

The Peptide Evidence Index

We checked 329 studies behind 10 peptides. 20% are randomised trials, and 1 compound has none at all.

Aug 19, 2026

AHK-Cu vs GHK-Cu: Only One Has Been Tested in People

GHK-Cu has decades of human trial data behind it. AHK-Cu's hair growth claims rest almost entirely on cell studies. Here is what separates them.

Aug 18, 2026

What's causing the 'copper peptide uglies'?

Copper peptide serums are well tolerated in trials. Reported breakouts and irritation often trace to formulation or other actives, not the peptide itself.

Aug 16, 2026

Copper peptide injections have almost no human evidence

GHK-Cu copper peptides are marketed for injection using evidence collected from topical creams. Here is what injectable human and animal data show.

Aug 15, 2026

Peptides vs GLP-1 drugs: the trial evidence isn't close

Semaglutide and tirzepatide have large randomized trials behind them. Most peptides sold for weight loss do not. Here is the evidence gap between them.

Aug 14, 2026

Cartalax's human evidence is one unsourced sentence

Cartalax is sold as a cartilage peptide bioregulator. The verified evidence is a chondrocyte senescence-marker finding; the human-use claim traces to one line in a review with no named trial.

Aug 13, 2026

GHK-Cu Peptide Injection: The Human Evidence Gap

GHK-Cu injections are marketed for skin, hair and wound healing. The controlled human trials that exist are almost all topical, not injectable. Here is the gap.

Jul 30, 2026

Best peptides for weight loss: only a few have real trials

Three peptides have large randomised weight-loss trials behind them. Most compounds sold as weight-loss peptides have little or nothing. Here is the split.

Jul 28, 2026

IGF-1 LR3 before and after: the photos are not evidence

IGF-1 LR3 has no published human trials. What the mecasermin data shows, why progress photos are not evidence, and the IGF-1 cancer association explained.

Jul 25, 2026

MOTS-c Dosing: Why No Human Number Exists Yet

Every MOTS-c dose circulating online traces back to rodent studies. What was administered, to what, and why no human dosing protocol exists.

Jul 24, 2026

Sermorelin FDA 503A Status: What the Record Shows

Sermorelin under FDA 503A compounding rules: what the regulatory record says, what changed, and what it means for legal access.

Jul 24, 2026

Sauna and the Heart: One Cohort, Repeated Everywhere

The sauna and heart-health findings come largely from one Finnish cohort. What it found, what the physiology supports, and why no trial has confirmed it.

Jul 24, 2026

Insulin Resistance and Heart Disease: How Tight Is the Link?

Insulin resistance tracks with cardiovascular disease well before diabetes appears. What the cohort data show, what genetics add, and where the causal claim stops.

Jul 24, 2026

Creatine and Cognition: A Small Effect in Specific Conditions

Creatine is well established for muscle. For the brain the evidence is thinner and conditional. What the trials show, in whom, and under what stress.

Jul 24, 2026

Resistance Training After 50: What the Trials Support

What randomized trials in adults over 50 show about resistance training for strength, muscle, bone and daily function, and what they do not establish.

Jul 24, 2026

Sleep Duration and Longevity: Reading the Curve Honestly

Both short and long sleep track with higher mortality. What that U-shaped curve establishes, what it cannot, and what follows for how you sleep.

Jul 21, 2026

GHK-Cu Injectable: Which Human Clinical Trials Exist

We searched PubMed and Europe PMC for human trials of injectable GHK-Cu. What exists, what the topical studies show, and why they do not transfer.

Jul 21, 2026

Semaglutide Clinical Trials: The Five That Matter

Five randomised semaglutide trials, what each one measured, how much weight participants lost, and the questions none of them answer.

Jul 20, 2026

BPC-157: Decades of Rat Data, Zero Human Trials

BPC-157's healing claims rest almost entirely on rodent studies. Here's what three decades of research establishes, and where it stops cold.

Jul 19, 2026

GHK-Cu's Gene-Expression Study, Read Carefully

A close read of the 2015 GHK-Cu gene-expression paper: what the Connectivity Map data shows, and why the systemic-modulator claim outruns the evidence.

Jul 18, 2026

Topical GHK-Cu: Strong Skin Data, Thin Everywhere Else

A source-grounded look at topical GHK-Cu: the human trials, the proposed mechanisms, published dosing, and where the copper peptide falls short of the hype.

Jul 18, 2026

What Is Tesamorelin? A Straight Answer for Researchers

A concise, evidence-graded primer on tesamorelin: origin, approved use, research doses, and what the trials show versus what's assumed.

Jul 18, 2026

Natural Peptides: Which Claims Have Human Trials

Collagen peptides have RCTs behind them. BPC-157 and TB-500 don't. A source-grounded look at what 'natural peptide' evidence means.

Jul 17, 2026

GHK-Cu: The Copper Peptide With Data Behind It

A source-grounded look at GHK-Cu's human trial data, proposed mechanisms, published dosing, and where it stands versus other peptides.

Jul 1, 2026

Tirzepatide Before and After: What the Trials Actually Measured

What SURMOUNT and SURPASS trials actually recorded on tirzepatide dosing, timelines, and outcomes, and where the published data stops.

Jun 19, 2026

GHK-Cu: Where the Research Is Strong and Where It Stops

A research-oriented primer on GHK-Cu: what it is, what the literature supports, where the evidence is thin, and what to read next.

Jun 16, 2026

GHK-Cu Benefits: Sorting Trials From Marketing

A deep-dive into GHK-Cu peptide: what human trials, animal studies, and cell-line work support, where the evidence is weak, and what researchers used for dosing.

Jun 15, 2026

CJC-1295 vs Alternatives: What the Evidence Shows

A deep-dive into CJC-1295 versus sermorelin, tesamorelin, and ipamorelin, what clinical trials show, where the gaps are, and which peptide has the stronger case.

Jun 15, 2026

GHK-Cu vs Matrixyl: which copper-collagen peptide actually works

GHK-Cu and Matrixyl both claim to rebuild collagen. Here's how their trial data, safety records, and practical use cases actually compare.

Jun 15, 2026

BPC-157 Before and After: Reports vs Trial Findings

A deep-dive into BPC-157's real evidence base: what animal studies show, what human data exists, mechanisms, dosing protocols, and where the science falls short.

Jun 15, 2026

TB-500 Explained: Evidence, Mechanism, and Dosing Reality

A source-grounded look at TB-500's human and animal evidence, mechanism, published dosing, and how it stacks up against BPC-157.

Jun 15, 2026

BPC-157 Results: Rat Data, Human Expectations

A source-grounded deep-dive into BPC-157 results across animal and human data, covering mechanisms, published dosing protocols, side effects, and what's still unknown.

Jun 13, 2026

Is BPC-157 Legal? The Regulatory Position

BPC-157 sits in a legal grey zone. Here is what the FDA, WADA, and international regulators have said, and what that means for research use.

Jun 12, 2026

BPC-157: What It Is and How Researchers Use It

A research-oriented primer on BPC-157: what it is, what the preclinical literature shows, how researchers dose it, and where the evidence ends.

Jun 12, 2026

BPC-157 Side Effects: The Safety Data Nobody Has

A critical breakdown of BPC-157 side effect data, from preclinical findings to the near-total absence of controlled human safety trials.

Jun 12, 2026

TB-500 vs BPC-157: Which Has the Better Evidence

TB-500 and BPC-157 compared on efficacy, safety, and practical use. See which peptide has stronger evidence for tissue repair and recovery decisions.

May 12, 2026

BPC-157 Oral Bioavailability: Myth vs. Evidence

The claim that BPC-157 is orally bioavailable circulates widely in peptide forums. Here is what the actual literature supports and where the myth breaks down.

May 12, 2026

Selank for Anxiety: What the Research Protocols Show

A source-anchored review of Selank research protocols for anxiety — doses, routes, durations, reported outcomes, and open questions from published studies.

May 12, 2026

TB-500 for Tendon Recovery: What the Evidence Shows

A deep-dive into TB-500's evidence base for tendon recovery, covering preclinical data, proposed mechanisms, published dosing protocols, and where it stands vs. alternatives.